|
Market Closed -
Nasdaq
16:00:00 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 0.4203 USD | -2.28% |
|
-4.24% | -90.88% |
Company Valuation: Titan Pharmaceuticals
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 11.14 | 23.29 | 10.11 | 11.46 | 6.215 | 2.98 |
| Change | - | 109.11% | -56.58% | 13.29% | -45.75% | -52.04% |
| Enterprise Value (EV) 1 | 10.36 | 18.68 | 4.374 | 8.706 | 0.0198 | 0.1494 |
| Change | - | 80.44% | -76.59% | 99.02% | -99.77% | 653.03% |
| P/E | -0.27x | -0.68x | -1.13x | -1.03x | -1.11x | -0.62x |
| PBR | 7.77x | 6.65x | 1.97x | 8.63x | 0.97x | 1.22x |
| PEG | - | 0x | 0x | 0.1x | 0x | 0x |
| Capitalization / Revenue | 3.08x | 4.81x | 6.63x | 20.6x | 33.8x | - |
| EV / Revenue | 2.87x | 3.86x | 2.87x | 15.6x | 0.11x | - |
| EV / EBITDA | -0.62x | -2.65x | -0.48x | -0.87x | -0x | -0.03x |
| EV / EBIT | -0.61x | -2.54x | -0.47x | -0.85x | -0x | -0.03x |
| EV / FCF | -1.12x | -5.01x | -0.96x | -1.84x | -0x | -0.07x |
| FCF Yield | -89.3% | -20% | -105% | -54.3% | -28,458% | -1,388% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -432 | -96.7 | -18.04 | -15.19 | -7.406 | -5.235 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3.611 | 4.838 | 1.526 | 0.557 | 0.184 | - |
| EBITDA 1 | -16.6 | -7.059 | -9.133 | -10.04 | -7.165 | -4.552 |
| EBIT 1 | -16.84 | -7.351 | -9.354 | -10.24 | -7.277 | -4.557 |
| Net income 1 | -16.46 | -18.24 | -8.776 | -10.21 | -5.569 | -4.706 |
| Net Debt 1 | -0.782 | -4.604 | -5.738 | -2.75 | -6.195 | -2.831 |
| Reference price 2 | 116.460 | 65.800 | 20.400 | 15.662 | 8.250 | 3.260 |
| Nbr of stocks (in thousands) | 95.6 | 354 | 496 | 731 | 753 | 914 |
| Announcement Date | 3/30/20 | 3/31/21 | 3/25/22 | 3/31/23 | 4/1/24 | 3/20/25 |
1USD in Million2USD
Estimates
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TTNP Stock
- Valuation Titan Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
